COVID-19 Vaccines

COMIRNATY concentrate for dispersion for injection, COVID-19 mRNA-Vaccine (nucleoside modified)

Marketing authorisation holder: BioNTech

Date of marketing authorisation: 21 December 2020

On 8 January 2021, the Summary of Product Characteristics (SmPC) was updated in order to allow to extract 6 (instead of previously 5) doses per container.

Summary of product characteristics and package leaflet

COVID-19 Vaccine Moderna dispersion for injection, COVID-19 mRNA-Vaccine (nucleoside modified)

Marketing authorisation holder: Moderna

Date of marketing authorisation: 06 January 2021

Summary of product characteristics and package leaflet

COVID-19 Vaccine AstraZeneca (COVID-19-Adenovirus-Vaccine)

Marketing authorisation holder: AstraZeneca
Date of marketing authorisation: 29 January 2021

The Austrian National Vaccination Panel recommends the use of Astra Zeneca's vaccine in the 18-64 age group.

COVID-19 vaccination: Astra Zeneca National Immunization Panel Recommendation Version 1.0, as of 02/01/2021

For the 65+ age group, immunologic and safety data are comparable to those for younger individuals.
Due to the small group size and the low number of cases of disease, it is not possible at this time to make a safe prognosis for this age group.

 

COVID-19 Vaccinations: Immunization recommendations of the National Vaccination Committee, Version 2.0, as of 23.02.2021

Information about authorised Covid-19 vaccines and those under evaluation can be found on the website of the European Medicines Agency (EMA).

 

keyboard_arrow_up to top